Euronext Paris has informed the AMF that by January 12, the final date set for the submission of orders in response to Biosynex's tender offer for Theradiag shares, it had received 2,826,997 shares.

In total, Biosynex holds 9,032,820 shares, representing 68.86% of the share capital and at least 68.56% of the voting rights. As the minimum shareholding requirement has been met, the offer has been successful.

Settlement and delivery of the tender offer will take place according to the timetable communicated by Euronext Paris. A subsequent publication will specify the dates and duration of the reopening of the offer.

Copyright (c) 2023 CercleFinance.com. All rights reserved.